# Cannabis Science and Research Digest: Nanostructured lipid carriers for intranasal… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-science-and-research-digest-nanostructured-lipid-carriers-for-i-sep-2026/ > **Published:** 2026-09-20T21:46:52-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:19-04:00 > **Clinical Summary:** cannabis science digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic These studies sit at very different levels of evidence, but together they point to two practical realities: withdrawal is a real pharmacologic problem, and delivery matters. The PP-01 trial suggests that combining a cannabinoid agonist with gabapentin may blunt the first day of withdrawal, which is exactly when many quit attempts fail. The epilepsy review is a reminder that oral CBD is not the only possible route, but intranasal nanocarriers remain a translational idea, not a treatment. The lyric study is not clinical pharmacology, yet it shows how often cannabis and other drugs are embedded in messaging that can shape expectations, especially in younger audiences. DigestCannabis ScienceRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Nanostructured lipid carriers for intranasal canna. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42751849/) A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us Across these papers, the strongest clinical signal comes from the 14-person inpatient crossover trial of PP-01, where nabilone plus gabapentin reduced cannabis withdrawal severity within 10 hours, reduced bothersomeness within 4 hours, and improved sleep quality and craving, with mild adverse events and no serious events. The epilepsy review does not provide human efficacy data, but it argues that intranasal nanostructured lipid carrier cannabidiol could improve brain delivery, lower dose requirements, and reduce systemic exposure compared with oral CBD, while the lyric analysis found cocaine mentioned in 82.6% of 121 songs, cannabis in 52.9%, and alcohol in 38.0%, showing how normalized drug references are in a youth-facing cultural product. Why This Matters For patients trying to stop cannabis, the PP-01 data suggest a plausible short-term withdrawal aid that may reduce early relapse pressure, especially when sleep and craving are the main barriers. For seizure care, the intranasal CBD concept matters because oral CBD can be limited by slow onset and variable exposure, but the current evidence is still preclinical and not ready to guide routine prescribing. Study SnapshotPost TypeCannabis Science and Research Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesSeptember 20, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Nanostructured lipid carriers for intran (Yashika et al., PubMed) [DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849]Study 2Cocaine, cannabis, champagne-pharmacolog (Spark et al., PubMed) [DOI: 10.1007/s00210-026-05904-7 | PMID: 42733016]Study 3Proof-of-concept trial of PP-01 for miti (Slagle et al., PubMed) [DOI: 10.1111/ajad.70202 | PMID: 42717263] Clinical Bottom Line This cannabis science and research digest preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Nanostructured lipid carriers for intranasal canna](#digest-card-2-digest-card-1-nanostructured-lipid-carriers-for-intranasal-canna) - [Digest Card 2 | Cocaine, cannabis, champagne-pharmacological and t](#digest-card-3-digest-card-2-cocaine-cannabis-champagne-pharmacological-and-t) - [Digest Card 3 | Proof-of-concept trial of PP-01 for mitigating can](#digest-card-4-digest-card-3-proof-of-concept-trial-of-pp-01-for-mitigating-can) Why These 3 Updates Belong Together This curated cannabis science and research digest brings together 3 key developments across clinical research, public health signals, and therapeutic data. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Nanostructured lipid carriers for intranasal canna **Title & Source:** [Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.](https://pubmed.ncbi.nlm.nih.gov/42751849/) (*PubMed*, 2026Sep17) **Lead Authors & Identifiers:** Yashika, Sachin Yadav, Anish Arora, Nisha Bharti, Kapil, Amandeep Singh. | **Primary Record:** DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849 Content lane: **Mechanism Watch**. **1. Scientific & Clinical Background:** This was a Phase 1b/2a randomized, double-blind, placebo-controlled, crossover inpatient trial in 14 adults with moderate to severe cannabis use disorder. Participants used cannabis daily or near daily at at least 1 gram per day and had a history of withdrawal, making this a high-risk withdrawal cohort. **2. Detailed Findings & Primary Data:** PP-01, a combination of nabilone and gabapentin, significantly reduced withdrawal severity by 10 hours after the first dose (p = .0222) and bothersomeness by 4 hours (p = .0063). Sleep quality and cannabis craving also improved after the first dose through discharge, and objective withdrawal measures improved as well. Adverse events were mild, with no serious adverse events reported. **3. Dr. Caplan’s Clinical & Practical Guidance:** This is a plausible short-term withdrawal aid for carefully selected patients who struggle most in the first day or two of abstinence. It is not yet a routine outpatient standard, and any real-world use would need attention to sedation, misuse risk, and follow-up beyond the inpatient window. **4. Study Boundaries & Methodological Limits:** The sample was very small and the study was short, so durability and generalizability are unknown. The inpatient setting also reduces the complexity of real-world relapse triggers and co-use patterns. Digest Card 2 | Cocaine, cannabis, champagne-pharmacological and t **Title & Source:** [Cocaine, cannabis, champagne-pharmacological and toxicological references in the lyrics of the German rapper Haftbefehl: a content analysis.](https://pubmed.ncbi.nlm.nih.gov/42733016/) (*PubMed*, 2026Sep14) **Lead Authors & Identifiers:** Carina Spark, Benjamin Krichevsky, Sebastian Schröder, Adrian Groh, Martin Schulze Westhoff, Martin Klietz, Stephan Greten, Carsten Stoetzer, Daniel Benjamin Jäger, Johannes Heck. | **Primary Record:** DOI: 10.1007/s00210-026-05904-7 | PMID: 42733016 Content lane: **Clinical Evidence Update**. **1. Scientific & Clinical Background:** This paper is a translational review of preclinical and formulation literature on intranasal cannabidiol delivered through nanostructured lipid carriers for Dravet syndrome and Lennox-Gastaut syndrome. It focuses on whether a nose-to-brain delivery system could overcome the limitations of oral CBD, such as slow onset and systemic exposure. **2. Detailed Findings & Primary Data:** The review summarizes animal and formulation data suggesting higher brain-to-plasma ratios, longer central exposure, and anticonvulsant effects at lower doses than free or oral CBD. It also highlights unresolved issues, including long-term safety, pediatric nasal physiology, disease-specific genetic models, and the need for properly designed clinical trials in DS and LGS. **3. Dr. Caplan’s Clinical & Practical Guidance:** This is a formulation concept worth watching, especially for families frustrated by oral CBD limitations. It should not be treated as evidence to prescribe intranasal NLC-CBD outside a trial, because there are no human efficacy or safety data in the target pediatric syndromes. **4. Study Boundaries & Methodological Limits:** The paper is not a clinical trial and does not provide patient-level outcomes. Its conclusions rest on preclinical models and translational assumptions that may not hold in children with severe epilepsy. Digest Card 3 | Proof-of-concept trial of PP-01 for mitigating can **Title & Source:** [Proof-of-concept trial of PP-01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder.](https://pubmed.ncbi.nlm.nih.gov/42717263/) (*PubMed*, 2026Sep09) **Lead Authors & Identifiers:** Ashley F Slagle, Jay Constantine, Harvey Kushner, Shelli Graham, Ginger Constantine. | **Primary Record:** DOI: 10.1111/ajad.70202 | PMID: 42717263 Content lane: **Clinical Evidence Update**. **1. Scientific & Clinical Background:** This was a content analysis of the lyrics from seven studio albums by the German rapper Haftbefehl, totaling 121 songs released between 2010 and 2022. The investigators coded explicit and contextual references to psychotropic substances, slang terms, and drug-related behavior. **2. Detailed Findings & Primary Data:** Cocaine was referenced in 82.6% of songs, cannabis in 52.9%, and alcohol in 38.0%. References to μ-opioid receptor agonists appeared in 9.1% of songs, amphetamine-type substances in 7.4%, and benzodiazepines were not referenced at all, while cocaine slang was especially varied. **3. Dr. Caplan’s Clinical & Practical Guidance:** This kind of analysis is useful for understanding the media environment that normalizes drug talk, especially for adolescents and young adults. It can inform counseling about exposure and expectations, but it does not tell clinicians how music exposure changes individual risk. **4. Study Boundaries & Methodological Limits:** The study is descriptive and limited to one artist, so it cannot be generalized to all German rap or to broader youth culture. It also cannot establish causation between lyrical content and substance use behavior. How Strong Is This Evidence? PP-01 has the strongest internal validity here because it was randomized, double-blind, placebo-controlled, and crossover, but it enrolled only 14 adults and was short, inpatient, and proof-of-concept. The epilepsy paper is a narrative translational review of preclinical work, useful for hypothesis generation but not for efficacy claims. The lyric analysis is a descriptive content study of 121 songs, which is solid for frequency counts but cannot establish behavioral effects. Where This Paper Deserves Skepticism The PP-01 findings may overestimate benefit because of the tiny sample, short exposure window, inpatient monitoring, and crossover design in a highly selected group with daily or near-daily use of at least 1 gram per day. The CBD delivery review depends on animal and formulation data, with no pediatric DS or LGS clinical trial results, and the lyric analysis cannot tell us whether references to cocaine or cannabis change use patterns, only that they are common. What This Paper Does Not Show These papers do not prove that PP-01 is effective for long-term abstinence, outpatient relapse prevention, or broader cannabis use disorder populations. They also do not show that intranasal nanostructured lipid carrier CBD is safe, effective, or superior to approved oral CBD in children with Dravet or Lennox-Gastaut syndrome. How This Fits With the Broader Clinical Conversation Cannabis withdrawal treatment is moving toward medication strategies that borrow from existing agents, especially when sleep disruption, craving, and early dropout drive relapse. At the same time, cannabinoid therapeutics are increasingly being rethought through drug-delivery science, where route, formulation, and brain exposure may matter as much as the molecule itself. The cultural study fits a broader public health pattern, where substance references in music and media are treated as part of the exposure environment, not just entertainment. That matters because prevention and counseling often have to compete with repeated normalization of drug use in the settings patients actually live in. Dr. Caplan’s Take *The PP-01 result is the kind of signal that gets attention because it addresses a real clinical bottleneck, the first few days of stopping cannabis. A medication that eases withdrawal, sleep, and craving could make a meaningful difference, but 14 patients is a very small base, so I would treat this as promising, not practice-changing. It is a reminder that withdrawal deserves the same seriousness we give to other substance syndromes.* *The intranasal CBD idea is scientifically interesting because oral cannabinoids are not always efficient, especially when the target is rapid central nervous system exposure. Still, the gap between a clever delivery platform and a usable pediatric epilepsy therapy is large. For now, the practical lesson is to be cautious about assuming that a better formulation automatically means better outcomes, because safety, dosing, and real-world tolerability usually decide that.* What a Careful Reader Should Take Away PP-01 looks promising for short-term cannabis withdrawal relief, but it needs larger outpatient trials before it can be considered established care. Intranasal CBD for epilepsy is an interesting translational concept, not a clinical recommendation, and the lyric study mainly shows how saturated youth culture can be with drug references. Evidence Interpretation Guide Table of Contents - [How to Interpret This Cannabis Science and Research Digest](#How_to_Interpret_This_Cannabis_Science_and_Research_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[What this means if you are trying to stop cannabis](#What_this_means_if_you_are_trying_to_stop_cannabis) - [How a clinician should read these data](#How_a_clinician_should_read_these_data) - [Safety signals and what is still unknown](#Safety_signals_and_what_is_still_unknown) - [What these papers suggest for health policy](#What_these_papers_suggest_for_health_policy) - [What the next studies need to answer](#What_the_next_studies_need_to_answer) - [Where overinterpretation would be a mistake](#Where_overinterpretation_would_be_a_mistake) - [What families should hear](#What_families_should_hear) - [Bottom-line synthesis](#Bottom-line_synthesis) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Cannabis Science and Research Digest These papers span a human withdrawal trial, a translational epilepsy review, and a cultural content analysis, so they answer very different questions. The useful habit is to separate what is already clinically actionable from what is only biologically plausible or socially descriptive. ### Three Rules for Critical Reading **1. Match the claim to the study type**The PP-01 trial can support short-term symptom reduction because it was randomized and blinded, but the CBD intranasal paper is a review of preclinical delivery science, not a patient outcome study. The lyric analysis can count references, but it cannot tell you whether those references change behavior. **2. Look for the endpoint that matters clinically**In the withdrawal trial, the meaningful endpoints were severity, bothersomeness, sleep, craving, and adverse events within hours of dosing. In the epilepsy paper, the missing endpoint is actual seizure reduction in children with Dravet or Lennox-Gastaut syndrome, which is the real test of usefulness. **3. Ask whether the sample can support the conclusion**Fourteen adults in a short inpatient crossover study can generate a signal, but not define standard care. A 121-song content analysis can show prevalence of drug references, but not public health impact, and a preclinical formulation review cannot establish pediatric safety or dosing. Key Evaluation Question What part of this evidence changes care today, and what part only justifies more research? The Patient Question Is this treatment ready for me now, or is it still being studied in a small group? The Bottom Line Use the study design, sample size, and endpoint to decide whether a finding is ready for practice or still in the research lane. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Nanostructured lipid carriers for intranasal . #### What this means if you are trying to stop cannabis The most practical finding here is the withdrawal trial. In 14 adults with moderate to severe cannabis use disorder, PP-01 reduced withdrawal severity and bothersomeness quickly, and sleep and craving improved too, which matters because those are the symptoms that often drive relapse in the first days. That said, this is not yet a standard treatment. It is a small inpatient proof-of-concept study, so the result is encouraging but not enough to assume the same benefit in outpatient care, in people with lower use, or over longer periods. Lens takeawayShort-term withdrawal relief looks promising, but it is still early evidence. #### How a clinician should read these data PP-01 is the only paper here with direct human efficacy data, and it targets a real clinical gap, early withdrawal management. The signal is strongest for symptom relief, sleep, and craving, but the study is too small to define dosing strategy, duration, or outpatient safety. The CBD delivery review is useful for formulation thinking, especially in pediatric epilepsy where oral exposure is imperfect, but it remains preclinical. The lyric analysis is best used as a cultural context piece when counseling adolescents, not as evidence for treatment decisions. Lens takeawayUse the withdrawal trial as hypothesis-generating, not definitive, clinical evidence. #### Safety signals and what is still unknown PP-01 was well tolerated in a tiny inpatient sample, with only mild adverse events and no serious events, but that does not settle sedation, interaction, or misuse risk in broader practice. The combination of nabilone and gabapentin also raises practical questions about cognitive effects and monitoring. For intranasal NLC-CBD, the safety gap is much larger. The review explicitly notes missing long-term safety data, uncertain pediatric nasal physiology, and the absence of human trial evidence in Dravet or Lennox-Gastaut syndrome. Lens takeawayNo serious harm signal appeared, but the safety database is still very thin. #### What these papers suggest for health policy The PP-01 study supports the case for larger, regulated trials of cannabis withdrawal medications, especially because there is no FDA-approved option. If future studies confirm benefit, this could affect treatment access, relapse prevention planning, and insurance coverage for withdrawal management. The intranasal CBD review points toward regulatory work on pediatric nanomedicine, trial design, and route-specific standards. The lyric study is a reminder that prevention policy also has to account for the media environment that repeatedly normalizes drug use. Lens takeawayThe policy need is bigger trials, clearer regulation, and better prevention context. #### What the next studies need to answer For PP-01, the next step is a larger outpatient trial with longer follow-up, relapse outcomes, and comparison against standard supportive care. It would also help to know which symptom cluster, sleep, craving, or irritability, is most responsive and whether benefit persists after discharge. For intranasal NLC-CBD, the field needs pediatric pharmacokinetics, safety, and seizure outcome data in actual Dravet and Lennox-Gastaut patients. For the lyric work, broader sampling across artists and linkage to behavioral outcomes would be needed before making public health claims. Lens takeawayThe next evidence must move from signals to durable, patient-centered outcomes. #### Where overinterpretation would be a mistake A 14-person crossover trial can look cleaner than it really is, because each participant serves as their own control and the inpatient setting reduces noise. That makes the signal interesting, but it also makes it easy to overread a short-term effect as a durable treatment effect. The CBD review is vulnerable to translational optimism, where better brain delivery in animals gets treated as if it will automatically translate to children. The lyric analysis is vulnerable to ecological fallacy, because frequency of references is not the same as frequency of use or harm. Lens takeawayInteresting signals are not the same as clinically established effects. #### What families should hear For families dealing with severe epilepsy, the intranasal CBD idea may sound attractive because it promises faster and more targeted delivery, but it is still experimental. The practical message is that oral CBD remains the reference point, and any new route needs real pediatric safety and seizure data before it can be trusted. For families dealing with cannabis withdrawal or a loved one trying to quit, the PP-01 result suggests that withdrawal is treatable and deserves medical attention. That can help reduce shame, but it should also set expectations that this is early research, not a ready-made solution. Lens takeawayFamilies should see promise, but not confuse promise with proof. #### Bottom-line synthesis The only direct human treatment signal here is PP-01 for cannabis withdrawal, and it is encouraging for early symptom relief in a very small sample. The epilepsy paper is a formulation roadmap, not a clinical result, and the lyric analysis is a cultural exposure map, not a behavior study. Taken together, these papers show how cannabis science now spans withdrawal medicine, drug delivery engineering, and social context. The common thread is that the next step has to be better human data, because that is what turns interesting ideas into usable care. Lens takeawayThe strongest evidence is for early withdrawal relief, not for new CBD delivery. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+Science+and+Research+Digest%3A+Nanostructured+lipid+carriers+for+intranasal...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-and-research-digest-nanostructured-lipid-carriers-for-i-sep-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-and-research-digest-nanostructured-lipid-carriers-for-i-sep-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+Science+and+Research+Digest%3A+Nanostructured+lipid+carriers+for+intranasal...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-science-and-research-digest-nanostructured-lipid-carriers-for-i-sep-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: PubMed, PubMed, PubMed](https://pubmed.ncbi.nlm.nih.gov/42751849/) Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Care](https://cedclinic.com/drcaplan/) Dr. Caplan’s physician-led clinical practice and comprehensive patient guidance. [Learn about CED Clinic](https://cedclinic.com/drcaplan/)[Cannabis Research Library](https://cedclinic.com/category/cannabis-science/) Rigorous physician analysis of peer-reviewed cannabinoid literature and clinical trials. [Explore the research](https://cedclinic.com/category/cannabis-science/)[Cannabis News and Regulatory Updates](https://cedclinic.com/category/cannabis-news/) In-depth physician coverage of legal and regulatory developments in cannabis. [Read news updates](https://cedclinic.com/category/cannabis-news/) ## Frequently Asked Questions What is covered in this cannabis science and research digest? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).